Regulations Governing Accreditation and Management of Drug Abuse Urine Testing and Medical Institutions Article 12

The applicant testing institution, within six months after passing the preliminary document review of Paragraph 3 of the preceding Article, shall complete three times of performance test and the inspection conducted by the executive institution on the drugs or metabolites of Paragraph 1 Subparagraph 5 of the preceding Article.Performance test shall include negative urine specimen, positive urine specimen mixed with the drug to be tested of a known concentration, and positive urine specimen with a concentration near to the cutoff value of the drug to be tested or its metabolite.The accuracy of performance test shall reach 90% or above, and false positive result may not occur. For 80% or more of the results, the difference between the measured value of the drug to be tested and the value nominated by the executive institution shall be within 20% or two standard deviations, and in no case the difference may be 50% or more.Where the performance test fails to satisfy the requirements in the preceding Paragraph, three times of performance test shall be conducted after the defects are corrected.Inspection shall be conducted in accordance with the relevant regulations of the drug abuse urine testing institutions. Where an applicant testing institution fails to pass the inspection, another inspection shall be performed additionally after the defects are corrected.
中文原文 濫用藥物尿液檢驗及醫療機構認可管理辦法第12條
檢驗機構應於前條第三項書面審查通過後六個月內,就前條第一項第五款提出之藥物或代謝物,完成執行機關三次績效監測及實地評鑑。
績效監測,應包括陰性尿液檢體、添加已知濃度待測藥物陽性尿液檢體及含有接近待測藥物或其代謝物閾值濃度之陽性尿液檢體。
績效監測之正確率應達百分之九十以上,並不得有偽陽性結果出現,其中待測藥物之定量值與執行機關標定值差距在百分之二十或二個標準差之內者,應達百分之八十以上,且不得有與標定值差距達百分之五十以上。
績效監測未達前項基準者,應於改進缺失後另進行三次績效監測。
實地評鑑,依濫用藥物尿液檢驗認證機構實地評鑑相關規定進行;未通過實地評鑑者,應於改進缺失後,另進行一次實地評鑑。

English translation for reference only; the Chinese text prevails. Not legal advice.